FDA ap­proves an­oth­er in­di­ca­tion for Keytru­da, this time in the ad­ju­vant NSCLC set­ting

Mer­ck’s block­buster can­cer treat­ment Keytru­da has been hand­ed an­oth­er in­di­ca­tion by the FDA.

The US reg­u­la­tor an­nounced on Thurs­day that it has ap­proved Keytru­da to serve as an ad­ju­vant treat­ment for non-small cell lung can­cer (NSCLC), which is its fifth in­di­ca­tion in NSCLC and 34th in­di­ca­tion over­all.

Ac­cord­ing to a Mer­ck re­lease, the ap­proval is based on da­ta from a Phase III tri­al, dubbed Keynote-091, which mea­sured dis­ease-free sur­vival in pa­tients who re­ceived chemother­a­py fol­low­ing surgery. The da­ta from Mer­ck dis­played that Keytru­da cut down on the risk of dis­ease re­cur­rence or death by 27% ver­sus place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER